Healthcare Industry News: Baxano
News Release - September 21, 2015
TranS1 Announces New Vice President of SalesHealthcare industry veteran John Miller will lead sales efforts for innovative medical device company’s AxiaLIF® product as well as future offerings
DENVER--(Healthcare Sales & Marketing Network)--TranS1®, a medical device company focused on designing, developing and marketing products to treat degenerative conditions of the spine, has named John Miller to the position of vice president, Sales.
A graduate of Indiana University, Miller brings more than 18 years of sales leadership, general management and marketing experience with leading medical device and orthopedic companies to the TranS1 team. He most recently held the position of vice president of Sales at SpineFrontier in Boston. Prior to that he served as sales director at Baxano Surgical in Raleigh-Durham, N.C.
“I’ve always been impressed with the benefits TranS1’s AxiaLIF product can provide to those suffering with chronic back pain,” said Miller. “I am excited to join the new ownership and help to re-introduce this revolutionary company and products.”
Restructured under new ownership in 2015, TranS1 will develop and support a product line that provides a foundation for living well, driven by surgeon innovation. The company’s primary product, AxiaLIF, offers many benefits compared to traditional surgical techniques for treating lower back pain, including minimal blood loss, reduced post-operative pain, faster recovery times and potentially shorter hospital stays and lower amounts of pain medication. AxiaLIF has been used in more than 14,000 procedures in the U.S. and has been featured in nearly 100 peer-reviewed publications establishing the product’s safety, efficacy and biomechanics.
“Feedback from both surgeons and their patients from around the country continue to tell us AxiaLIF is a positive alternative for patients, allowing them to return to their lives more quickly and with less risk than traditional procedures,” said Jeff Schell, president and CEO.
Headquartered in Denver, TranS1 was restructured under new ownership in 2015 and features a product line that provides a foundation for living well driven by surgeon innovation. The restructured TranS1 team includes experienced research and development, sales and professional education professionals who are focused on resilient and continuous training of its sales force and physician customers, employing best-in-class training methods that ultimately benefit patients. TranS1’s primary product, AxiaLIF, provides a strong foundation upon a healthy L5-S1 joint to enable patients to live well. For more information, please visit www.TranS1.com.
Issuer of this News Release is solely responsible for its
Please address inquiries directly to the issuing company.